Accreditation

For Donors & Patients | Annual Meeting |

Resources

National Blood Foundation | AABB Store | Login |

Advocacy

Involved

Search Q

HOME | NEWS & RESOURCES | ARTICLE

# **News & Resources** News AABB Newsfeed AABB News Magazine TRANSFUSION Journal Resources +

# NIH, FDA ANNOUNCE GENE THERAPIES **CONSORTIUM TO FOCUS ON RARE DISEASES**

November 02, 2021

The National Institutes of Health (NIH) and Food and Drug Administration will partner with 10 pharmaceutical companies and five non-profit organizations to accelerate the development of gene therapies through the newly launched Bespoke Gene Therapy Consortium (BGTC). The consortium aims to optimize and streamline the gene therapy development process to help fill the unmet medical needs of people with rare diseases. NIH and private partners will contribute approximately \$76 million throughout the course of the next five years to support BGTC-funded projects.

BGTC researchers will examine the biological and mechanistic steps involved in adeno-associated virus (AAV) vector production, vector delivery of genes into human cells and how therapeutic genes are activated in target cells. These results will provide information for improving the efficiency of vector manufacturing and enhancing the overall therapeutic benefit of AAV gene therapy. The program will also develop a standard set of analytic tests to apply to the manufacture of viral vectors made by consortium researchers. Such tests could be broadly applicable to different manufacturing methods and make the process of developing gene therapies for very rare conditions much more efficient. Additionally, the BGTC will explore methods to streamline regulatory requirements and processes for the FDA approval of safe and effective gene therapies.

## Related News

#### FDA Approves First Drug to Prevent aGVHD

December 17, 2021

The Food and Drug Administration approved abatacept (Orencia, Bristol Myers Squibb) yesterday to prevent acute graft versus host disease (aGVHD) in combination with certain immunosuppressants.

# White House Hosts Inaugural Maternal Health Day of Action

December 15, 2021

Vice President Kamala Harris issued a nationwide call to action to combat maternal morbidity and mortality Dec. 7 as part of the Biden Administration's inaugural White House Day of Action on maternal health.

## CMS Halts Vaccine Requirement for **Health Care Workers Following** Injunctions

December 8, 2021

The Centers for Medicare and Medicaid Services (CMS) has suspended enforcement of its recent COVID-19 vaccine mandate for health care workers while there are courtordered injunctions in place prohibiting its enforcement.



AABB is now the Association for the Advancement of Blood & Biotherapies. Learn more about our new name and brand - and watch as we evolve throughout 2022.

MEMBERSHIP	STANDARDS & ACCREDITATION	NEWS & RESOURCES	EDUCATION	REGULATORY & ADVOCACY	ABOUT AABB	GET INVOLVED
Prospective Members	Standards	News	Calendar of Events	Regulatory Affairs	Organization	Join AABB
Member Benefits	About AABB Standards	AABB Newsfeed	Annual Meeting	Regulatory for Blood and Blood Components	AABB History	Volunteer
Join AABB	Purchase Standards	AABB News Magazine	Meetings On-Demand	Regulatory Resources	Governance & Policies	Awards
	Standards Portal	TRANSFUSION Journal	eCasts	Infectious Diseases	Disaster Response	AABB Memorial Awards
Current Members	Accreditation		Hot Topic Discussions	Government Advisory &	Press	NBF Award for Innovative Research
My Account		Resources	Courses	Regulatory Meetings	Contact Us	ct Us RISE Award
Renew My Membership Membership Directory	Accreditation Overview  Become AABB-Accredited	Transfusion Medicine Biotherapies	Certificate Programs Science & Innovation	Regulatory for Cellular Therapies	Corporate Services	President's Awards  AABB Future Leader
Committees & Sections	Accreditation Portal	Patient Blood Management	Forums Publications	Advocacy	National Blood Exchange	Scholarship Awards
	Accredited Member Tools	Hemovigilance	Access My Learning	Advocacy Agenda	Consulting Services	Program 2021 AABB Award
	Assessor Information	Clinical Resources	Programs	Comments to FDA	Global Services	Recipients
	Accredited Facilities  AABB Commendable	Association Bulletins	CE/CME Information	Blood Sustainability	AABB Corporate Partner Program	List of Past AABB Awards Recipients
	Practices	Circular of Information Donor History Questionnaires Billing Guide	AABB HUB	Patient & Donor Safety Cellular Therapies & Biotherapies Coverage & Reimbursement	Supplier Guide Advertising and Sponsorship Opportunities FDA Third Party Review	AABB HUB Committees & Sections
		Job Board		Nambarsement	SCoPE Program	

Privacy Policy | Terms of Use



4550 Montgomery Avenue Suite 700, North Tower Bethesda, MD 20814 301.907.6977

www.aabb.org

**OUR SOCIAL MEDIA** 







AABB (Association for the Advancement of Blood & Biotherapies) is an international, not-for-profit organization representing individuals and institutions involved in the fields of transfusion medicine and biotherapies. The Association works collaboratively to advance the field through the development and delivery of standards, accreditation and education programs. AABB is dedicated to its mission of improving lives by making transfusion medicine and biotherapies safe, available and effective worldwide.